[{"id":"fb516173-31d7-494e-97c4-4ff3638b1c22","acronym":"","url":"https://clinicaltrials.gov/study/NCT05439499","created_at":"2022-06-30T17:02:23.698Z","updated_at":"2024-07-02T16:36:07.739Z","phase":"Phase 3","brief_title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","source_id_and_acronym":"NCT05439499","lead_sponsor":"Ahon Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • goserelin acetate • Futuoning (fovinaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 434","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 09/20/2024","primary_completion_date":" 09/20/2024","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2022-07-06"},{"id":"7f1eb2a8-7ae8-4950-8781-bce319cd5386","acronym":"","url":"https://clinicaltrials.gov/study/NCT05438810","created_at":"2022-06-30T17:02:15.633Z","updated_at":"2024-07-02T16:36:07.814Z","phase":"Phase 3","brief_title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","source_id_and_acronym":"NCT05438810","lead_sponsor":"Ahon Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • goserelin acetate • Futuoning (fovinaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 02/18/2024","primary_completion_date":" 02/18/2024","study_txt":" Completion: 05/18/2024","study_completion_date":" 05/18/2024","last_update_posted":"2022-07-04"},{"id":"1112364d-b294-430a-b5a7-1dcfd272a32f","acronym":"FCN-437c-001","url":"https://clinicaltrials.gov/study/NCT03951116","created_at":"2021-01-18T19:26:51.225Z","updated_at":"2024-07-02T16:36:15.287Z","phase":"Phase 1","brief_title":"Study of FCN-437c in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03951116 - FCN-437c-001","lead_sponsor":"Fochon Pharmaceuticals, Ltd.","biomarkers":" KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • ALK translocation","tags":["KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Futuoning (fovinaciclib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 06/25/2019","start_date":" 06/25/2019","primary_txt":" Primary completion: 12/08/2021","primary_completion_date":" 12/08/2021","study_txt":" Completion: 12/08/2021","study_completion_date":" 12/08/2021","last_update_posted":"2022-03-16"},{"id":"d5979198-ef29-40a6-8d6c-7e0a45310fe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004142","created_at":"2021-08-13T12:53:25.340Z","updated_at":"2024-07-02T16:36:26.399Z","phase":"Phase 2","brief_title":"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin","source_id_and_acronym":"NCT05004142","lead_sponsor":"Ahon Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • goserelin acetate • Futuoning (fovinaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-08-13"},{"id":"f67b200f-857a-4f84-87a3-a7c679e506e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04488107","created_at":"2021-01-18T21:32:37.920Z","updated_at":"2024-07-02T16:36:42.725Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c","source_id_and_acronym":"NCT04488107","lead_sponsor":"Ahon Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • Futuoning (fovinaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-07-27"}]